WAY Stock Forecast & Price Target

Waystar Holding is viewed positively because it combines mission-critical healthcare workflow software with a durable data moat, 30,000+ clients, 5k+ payor connections, and roughly 8.5B annual transactions that support strong recurring revenue and high customer stickiness. Management reaffirmed low-double-digit growth, >97% gross revenue retention, 108–110% NRR, ~70% EBITDA-to-FCF conversion, and 40%+ adjusted EBITDA margins, while the platform’s AI-driven Altitude suite and vendor-consolidation use cases expand cross-sell opportunities across a $44.1B TAM. The outlook is further strengthened by the company’s ability to reduce denials, automate labor-intensive revenue-cycle tasks, and preserve competitive differentiation versus EHR-native and horizontal AI rivals through proprietary claims data and end-to-end orchestration.

Waystar Holding is facing a weaker fundamental setup because elongated enterprise sales cycles, especially the 12–18 month hospital process, can delay bookings and push out revenue recognition. Its outlook is also pressured by a highly competitive, fragmented market where entrenched EHR vendors and emerging AI-based tools can erode share, while the company’s growth may normalize after a $34mm 2024 benefit tied to the Change Healthcare fallout and top-line growth of 19.3% in 2024 versus 12.2% in FY23. Added to that, roughly 50% volume-based revenue, rising cybersecurity and compliance risk, and the bear case’s mid-single-digit organic growth with EBITDA margin compression all point to downside.